EGFR and non-small cell lung carcinoma: 3.3 PAbs affect the cell viability in NSCLC cell lines resistant to anti-HER1 therapies where combinations of MAbs are not effective, and elicit an antitumor effect in models of sensitivity or resistance to HER1-targeting therapies